Naomi Kresge

  • Lars Fruergaard Jorgensen, CEO of Danish drugmaker Novo Nordisk, maker of the blockbuster diabetes and weight-loss treatments Ozempic and Wegovy, presents the annual report at Novo Nordisk in Bagsvaerd, Denmark, on February 5, 2025. Danish drugmaker Novo Nordisk, maker of the blockbuster diabetes and weight-loss treatments Ozempic and Wegovy, said on Wednesday its net profit jumped 21 percent in 2024 to 100 billion Danish kroner ($13.9 billion). Europe’s most valuable company said its sales rose 25 percent to 290.4 billion Danish kroner, propelled by its popular injections. (Photo by Mads Claus Rasmussen / Ritzau Scanpix / AFP) / Denmark OUT (Photo by MADS CLAUS RASMUSSEN/Ritzau Scanpix/AFP via Getty Images)Finance

    Ozempic CEO’s exit from Novo started with Teams call surprise

    By Naomi Kresge and Bloomberg
  • Adam Steensberg, chief executive officer of Zealand Pharma A/S, during an interview in London, UK, on Wednesday, Aug. 21, 2024. Steensberg leads the Danish drugmaker that’s seen its stock rise by more than 800% since he took over in 2022. Photographer: Betty Laura Zapata/Bloomberg via Getty ImagesRetail

    Roche, Zealand Pharma in $5.3 billion pact for obesity drugs

    By Paula Doenecke, Naomi Kresge, and others
  • GENEVA, SWITZERLAND – JANUARY 23: The headquarters of the World Health Organization (WHO) stands on January 23, 2025 in Geneva, Switzerland. U.S. President Donald Trump has announced he will seek to withdraw the U.S. from the WHO, claiming the U.S. pays disproportionately too much into the institution. The WHO, which is a part of the United Nations and has 194 member states, is the world’s biggest intergovernmental organization tasked with public health. It plays an especially crucial role in coordinating and implementing responses to outbreaks of epidemic diseases. (Photo by Robert Hradil/Getty Images)Health

    WHO offers early retirement to cut costs ahead of U.S. exit

    By Bloomberg, Ashleigh Furlong, and others
  • Semaglutide medications Wegovy and Ozempic are picturedHealth

    Wegovy, Ozempic shortage declared over, hitting copycats like Hims & Hers

    By Bloomberg, Madison Muller, and others
  • Lars Fruergaard Jorgensen, chief executive officer Novo Nordisk A/S, arrives for a Senate Health, Education, Labor, and Pensions Committee hearing in Washington, DC, US, on Tuesday, Sept. 24, 2024. The Danish company faces increasing pressure to make its medicines more affordable as demand skyrockets, with many patients paying out-of-pocket to use them for weight loss since some insurers don’t cover it. Photographer: Al Drago/Bloomberg via Getty ImagesRetail

    Novo Nordisk’s Wegovy sales jump on international rollouts

    By Naomi Kresge and Bloomberg
  • A person holds up a box of Ozempic.Health

    Ozempic may help manage opioid addiction: study

    By Naomi Kresge and Bloomberg
  • Sen. Bernie Sanders is seen pointing and speaking at the opening of a Senate committee hearing.Politics

    Bernie Sanders grills Ozempic maker over high prices, accuses company of endangering lives

    By Madison Muller, Naomi Kresge, and others
  • Thomas Schinecker, chief executive officer of Roche Holding AG, during an earnings news conference at the company’s headquarters in Basel, Switzerland, on Thursday, Feb. 1, 2024. Roche forecast a sluggish recovery in sales and earnings this year as it emerges from a difficult 2023 and a string of research setbacks. Photographer: Pascal Mora/Bloomberg via Getty ImagesHealth

    Roche stock is falling after report its Wegovy challenger is causing patients to vomit

    By Naomi Kresge and Bloomberg
  • Thomas Schinecker, CEO of Roche Holding.Retail

    An obesity pill study tested on just 25 patients led to a stunning $16.8 billion increase in Swiss drugmaker Roche’s market value

    By Naomi Kresge, Lisa Pham, and others
  • Lars Fruergaard Jorgensen, CEO of Novo Nordisk.Health

    A rare setback as Ozempic-maker Novo Nordisk takes a $820 million hit as its next wonder drug fails

    By Naomi Kresge and Bloomberg
  • A pharmacist holds a box of Novo Nordisk A/S Ozempic brand semaglutide medication arranged at a pharmacy in Provo, Utah, US, on Monday, Nov. 27, 2023. Prescriptions of appetite suppressing GLP-1 weight-loss drugs skyrocketed 300% from 2020 to 2022. Photographer: George Frey/Bloomberg via Getty ImagesHealth

    EU urges clampdown on cosmetic misuse of Novo’s Ozempic amid worsening drug shortages for diabetics

    By Naomi Kresge and Bloomberg
  • Lars Fruergaard Jorgensen, CEO of Novo Nordisk.Health

    Novo Nordisk plots $4.1 billion in U.S. factory amid Ozempic shortage, the same day it pulled out of its Ireland development project

    By Naomi Kresge and Bloomberg
  • Timotheus Höttges, CEO of Deutsche Telekom.Finance

    Germany just offloaded $2.7 billion in one of its largest companies so it can bolster its railway networks

    By Swetha Gopinath, Naomi Kresge, and others
  • Plumes of smoke are seen after a fire broke out at an office building belonging to Danish pharmaceutical group Novo Nordisk in Bagsvaerd near Copenhagen, Denmark, on May 22, 2024.Retail

    Danish pharma giant Novo Nordisk’s office building is in danger of collapsing after a ‘massive fire’ broke out

    By Sanne Wass, Naomi Kresge, and others
  • Lars Fruergaard Jorgensen, chief executive officer Novo NordiskRetail

    Denmark’s Novo Nordisk forecasts 27% sales surge but faces price pressure amid Eli Lilly competition

    By Naomi Kresge and Bloomberg